EMBC

+ Watchlist + Portfolio

Embecta Corp.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $5.42
52-Week Range: $2.77 – $15.55
Market Cap: $309.93M
P/E (TTM): 3.72
EPS (TTM): 1.47
Dividend Yield: 0.74%

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: 12.24%
Gross Margin: 58.42%
Operating Margin: 23.67%
Profit Margin: 8.59%
Current Ratio: 1.68
Debt/Equity: —
Total Debt: $1.50B
Free Cash Flow: $138.20M
Revenue Growth: -8.10%
Earnings Growth: -53.70%
Enterprise Value: $1.60B

EMBC Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$1.13B	$1.12B	$1.12B	$1.08B
Cost of Revenue	$354.60M	$370.90M	$387.90M	$403.60M
Gross Profit	$774.90M	$749.90M	$735.20M	$676.80M
Research & Development	$66.90M	$85.20M	$78.80M	$37.30M
Selling, General & Admin	$294.80M	$341.30M	$365.10M	$332.00M
Operating Expenses	$406.40M	$525.90M	$450.20M	$380.40M
Operating Income	$368.50M	$224.00M	$285.00M	$296.40M
EBITDA	$334.50M	$245.30M	$192.70M	$284.30M
Pretax Income	$256.60M	$105.70M	$44.20M	$136.30M
Income Tax	$33.00M	$35.30M	-$34.10M	$40.90M
Net Income	$223.60M	$70.40M	$78.30M	$95.40M
Diluted EPS	3.89	1.22	1.34	1.62
Diluted Shares	57.48M	57.70M	58.33M	58.91M

EMBC Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$330.90M	$326.30M	$267.50M	$225.50M
Receivables	$133.10M	$159.10M	$246.80M	$148.90M
Inventory	$122.80M	$152.10M	$171.50M	$178.60M
Current Assets	$664.70M	$749.10M	$761.00M	$631.40M
Total Assets	$1.09B	$1.21B	$1.29B	$1.09B
Current Liabilities	$301.00M	$353.50M	$374.00M	$261.50M
Long-Term Debt	$1.60B	$1.59B	$1.57B	$1.39B
Total Debt	$1.64B	$1.64B	$1.61B	$1.43B
Total Liabilities	$1.98B	$2.04B	$2.02B	$1.74B
Retained Earnings	-$577.10M	-$541.10M	-$498.60M	-$445.60M
Shareholders' Equity	-$891.40M	-$821.70M	-$738.90M	-$651.20M
Working Capital	$363.70M	$395.60M	$387.00M	$369.90M
Net Debt	$1.28B	$1.28B	$1.31B	$1.17B

EMBC Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$412.20M	$67.70M	$35.70M	$191.70M
Capital Expenditure	-$24.00M	-$26.50M	-$15.80M	-$9.30M
Free Cash Flow	$388.20M	$41.20M	$19.90M	$182.40M
Depreciation & Amortisation	$31.70M	$32.60M	$36.20M	$40.70M
Stock-Based Compensation	$18.70M	$21.50M	$26.30M	$31.60M
Investing Cash Flow	-$24.00M	-$26.50M	-$15.80M	-$9.30M
Financing Cash Flow	-$48.00M	-$48.70M	-$73.40M	-$226.70M
Dividends Paid	-$8.60M	-$34.40M	-$34.50M	-$35.00M
Net Change in Cash	$340.20M	-$7.50M	-$53.50M	-$44.30M

EMBC Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$259.00M	$295.50M	$264.00M	$261.20M	$221.80M
Cost of Revenue	$94.90M	$98.40M	$105.50M	$99.50M	$94.00M
Gross Profit	$164.10M	$197.10M	$158.50M	$161.70M	$127.80M
Research & Development	$8.00M	$4.40M	$4.60M	$4.60M	$5.40M
Selling, General & Admin	$79.60M	$84.40M	$86.90M	$77.60M	$76.20M
Operating Expenses	$90.40M	$92.10M	$94.20M	$85.40M	$84.90M
Operating Income	$73.70M	$105.00M	$64.30M	$76.30M	$42.90M
EBITDA	$74.20M	$110.60M	$60.40M	$95.90M	$44.90M
Pretax Income	$35.80M	$72.20M	$29.00M	$58.90M	$9.50M
Income Tax	$12.30M	$26.70M	$2.60M	$14.80M	$13.60M
Net Income	$23.50M	$45.50M	$26.40M	$44.10M	-$4.10M
Diluted EPS	0.40	0.78	0.45	0.74	-0.07
Diluted Shares	58.55M	58.49M	58.87M	59.29M	59.40M

EMBC Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$209.30M	$230.60M	$225.50M	$201.30M	$184.90M
Receivables	$202.60M	$192.90M	$148.90M	$159.20M	$147.10M
Inventory	$169.20M	$189.90M	$178.60M	$181.80M	$192.60M
Current Assets	$643.40M	$681.50M	$631.40M	$620.20M	$608.10M
Total Assets	$1.12B	$1.16B	$1.09B	$1.06B	$1.03B
Current Liabilities	$259.30M	$275.50M	$261.50M	$234.70M	$247.30M
Long-Term Debt	$1.51B	$1.46B	$1.39B	$1.35B	$1.32B
Total Debt	$1.55B	$1.50B	$1.43B	$1.39B	$1.36B
Total Liabilities	$1.86B	$1.83B	$1.74B	$1.68B	$1.66B
Retained Earnings	-$493.50M	-$457.10M	-$445.60M	-$411.10M	-$424.70M
Shareholders' Equity	-$736.20M	-$669.60M	-$651.20M	-$613.10M	-$626.10M
Working Capital	$384.10M	$406.00M	$369.90M	$385.50M	$360.80M
Net Debt	$1.31B	$1.24B	$1.17B	$1.16B	$1.14B

EMBC Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	$31.80M	$81.20M	$84.00M	$17.20M	$31.10M
Capital Expenditure	-$100.00K	-$400.00K	-$7.30M	-$600.00K	-$500.00K
Free Cash Flow	$31.70M	$80.80M	$76.70M	$16.60M	$30.60M
Depreciation & Amortisation	$11.70M	$11.80M	$5.30M	$12.90M	$12.80M
Stock-Based Compensation	$7.30M	$5.90M	$9.50M	$5.90M	$5.70M
Investing Cash Flow	-$100.00K	-$400.00K	-$7.30M	$9.50M	-$500.00K
Financing Cash Flow	-$37.30M	-$62.60M	-$81.60M	-$51.60M	-$41.50M
Dividends Paid	-$8.70M	-$8.70M	-$8.80M	-$8.90M	-$8.90M
Net Change in Cash	-$5.60M	$18.20M	-$4.90M	-$24.90M	-$10.90M

Market Snapshot

About

Embecta Corp. is a global medical device company focused on diabetes care solutions. The company manufactures and distributes insulin delivery devices, including pen needles and syringes, serving millions of people with diabetes worldwide. Embecta was spun off from Becton, Dickinson and Company in 2022 to operate as an independent diabetes care specialist. The company maintains manufacturing facilities and distribution networks across North America, Europe, and Asia-Pacific, generating revenue through sales to pharmacies, distributors, and healthcare institutions.